CL2015000408A1 - Compuestos derivados de pirazolo[4,3-d]pirimidina y sus sales; composicion farmaceutica que los comprende, util para el tratamiento de enfermedades alergicas, inflamatorias, infecciosas o cancer. - Google Patents

Compuestos derivados de pirazolo[4,3-d]pirimidina y sus sales; composicion farmaceutica que los comprende, util para el tratamiento de enfermedades alergicas, inflamatorias, infecciosas o cancer.

Info

Publication number: CL2015000408A1
Authority: CL; Chile
Prior art keywords: pyrazolo; allergic; pyrimidine; infectious; inflammatory
Prior art date: 2012-08-24

Application number

CL2015000408A

Other languages

English (en)

Inventor

Diane Mary Coe

Stephen Allan Smith

Original Assignee

Glaxosmithkline Ll

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-08-24

Filing date

2015-02-20

Publication date

2015-04-24

2015-02-20 Application filed by Glaxosmithkline Ll filed Critical Glaxosmithkline Ll

2015-04-24 Publication of CL2015000408A1 publication Critical patent/CL2015000408A1/es

Links

206010028980 Neoplasm Diseases 0.000 title 1
230000000172 allergic effect Effects 0.000 title 1
208000010668 atopic eczema Diseases 0.000 title 1
201000011510 cancer Diseases 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
208000015181 infectious disease Diseases 0.000 title 1
230000002458 infectious effect Effects 0.000 title 1
230000002757 inflammatory effect Effects 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
DSKLYHDHQJANOE-UHFFFAOYSA-N pyrazolo[4,3-d]pyrimidine Chemical compound C1=NC=N[C]2C=NN=C21 DSKLYHDHQJANOE-UHFFFAOYSA-N 0.000 title 1
150000003839 salts Chemical class 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Microbiology (AREA)
Mycology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Otolaryngology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CL2015000408A 2012-08-24 2015-02-20 Compuestos derivados de pirazolo[4,3-d]pirimidina y sus sales; composicion farmaceutica que los comprende, util para el tratamiento de enfermedades alergicas, inflamatorias, infecciosas o cancer. CL2015000408A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261692853P	2012-08-24	2012-08-24
US201361774094P	2013-03-07	2013-03-07

Publications (1)

Publication Number	Publication Date
CL2015000408A1 true CL2015000408A1 (es)	2015-04-24

Family

ID=49085221

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2015000408A CL2015000408A1 (es)	2012-08-24	2015-02-20	Compuestos derivados de pirazolo[4,3-d]pirimidina y sus sales; composicion farmaceutica que los comprende, util para el tratamiento de enfermedades alergicas, inflamatorias, infecciosas o cancer.

Country Status (26)

Country	Link
US (5)	US9173872B2 (es)
EP (1)	EP2888264B1 (es)
JP (1)	JP6196674B2 (es)
KR (1)	KR20150046267A (es)
CN (1)	CN104755480B (es)
AR (1)	AR092198A1 (es)
AU (1)	AU2013305790B2 (es)
BR (1)	BR112015003259A2 (es)
CA (1)	CA2880576A1 (es)
CL (1)	CL2015000408A1 (es)
CR (1)	CR20150061A (es)
DO (1)	DOP2015000027A (es)
EA (1)	EA026354B1 (es)
ES (1)	ES2653254T3 (es)
HK (1)	HK1211029A1 (es)
IL (1)	IL236983B (es)
MX (1)	MX359671B (es)
MY (1)	MY175676A (es)
NZ (1)	NZ704224A (es)
PE (1)	PE20150730A1 (es)
PH (1)	PH12015500401A1 (es)
SG (1)	SG11201500787YA (es)
TW (1)	TWI625331B (es)
UA (1)	UA114109C2 (es)
UY (1)	UY34987A (es)
WO (1)	WO2014031815A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA103195C2 (uk)	2008-08-11	2013-09-25	Глаксосмитклайн Ллк	Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
WO2013014052A1 (en)	2011-07-22	2013-01-31	Glaxosmithkline Llc	Composition
US9173872B2 (en)	2012-08-24	2015-11-03	Glaxosmithkline Llc	Pyrazolopyrimidine compounds
JP6216387B2 (ja)	2012-11-20	2017-10-18	グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅＬＬＣ	新規化合物
SMT201700378T1 (it)	2012-11-20	2017-09-07	Glaxosmithkline Llc	Nuovi composti
KR20150085081A (ko)	2012-11-20	2015-07-22	글락소스미스클라인 엘엘씨	신규 화합물
WO2019209811A1 (en)	2018-04-24	2019-10-31	Bristol-Myers Squibb Company	Macrocyclic toll-like receptor 7 (tlr7) agonists
US11554120B2 (en)	2018-08-03	2023-01-17	Bristol-Myers Squibb Company	1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
CN110772523B (zh) *	2019-11-07	2020-06-26	黑龙江中医药大学	一种用于防治肾病的药物组合物
KR20220132594A (ko)	2020-01-27	2022-09-30	브리스톨-마이어스 스큅 컴퍼니	톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물
CN115210235A (zh)	2020-01-27	2022-10-18	百时美施贵宝公司	作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物
JP2023512206A (ja)	2020-01-27	2023-03-24	ブリストル－マイヤーズスクイブカンパニー	トール様受容体７（ＴＬＲ７）アゴニストとしての１Ｈ－ピラゾロ［４，３－ｄ］ピリミジン化合物
JP7684316B2 (ja)	2020-01-27	2025-05-27	ブリストル－マイヤーズスクイブカンパニー	トール様受容体７（ＴＬＲ７）アゴニストとしての１Ｈ－ピラゾロ［４，３－ｄ］ピリミジン化合物
US20230127326A1 (en)	2020-01-27	2023-04-27	Bristol-Myers Squibb Company	C3-SUBSTITUTED 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
JP7712941B2 (ja)	2020-01-27	2025-07-24	ブリストル－マイヤーズスクイブカンパニー	トール様受容体７（ＴＬＲ７）アゴニストとしての１Ｈ－ピラゾロ［４，３－ｄ］ピリミジン化合物
CN115279765B (zh)	2020-01-27	2024-11-12	百时美施贵宝公司	作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物
WO2021154662A1 (en)	2020-01-27	2021-08-05	Bristol-Myers Squibb Company	1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
CN115151547A (zh)	2020-01-27	2022-10-04	百时美施贵宝公司	作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW574214B (en)	1994-06-08	2004-02-01	Pfizer	Corticotropin releasing factor antagonists
US7125880B1 (en)	1995-06-06	2006-10-24	Pfizer Inc.	Corticotropin releasing factor antagonists
US6403599B1 (en)	1995-11-08	2002-06-11	Pfizer Inc	Corticotropin releasing factor antagonists
AU3176297A (en)	1996-06-25	1998-01-14	Novartis Ag	Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof
US5985848A (en)	1997-10-14	1999-11-16	Albert Einstein College Of Medicine Of Yeshiva University	Inhibitors of nucleoside metabolism
TW572758B (en)	1997-12-22	2004-01-21	Sumitomo Pharma	Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
US6187777B1 (en)	1998-02-06	2001-02-13	Amgen Inc.	Compounds and methods which modulate feeding behavior and related diseases
US6232320B1 (en)	1998-06-04	2001-05-15	Abbott Laboratories	Cell adhesion-inhibiting antiinflammatory compounds
CZ27399A3 (cs)	1999-01-26	2000-08-16	Ústav Experimentální Botaniky Av Čr	Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
US20030187261A1 (en)	2000-01-07	2003-10-02	Libor Havlicek	Purine derivatives, process for their preparation and use thereof
TWI310035B (en)	2000-04-28	2009-05-21	Acadia Pharm Inc	Muscarinic agonists
GB0114286D0 (en)	2001-06-12	2001-08-01	Hoffmann La Roche	Nucleoside Derivatives
TW200301251A (en)	2001-12-20	2003-07-01	Wyeth Corp	Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
ATE478872T1 (de)	2002-03-28	2010-09-15	Ustav Ex Botan Av Cr V V I I O	Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung
BR0309581A (pt)	2002-05-06	2005-03-29	Genelabs Tech Inc	Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c
US6713241B2 (en)	2002-08-09	2004-03-30	Eastman Kodak Company	Thermally developable emulsions and imaging materials containing binder mixture
US7553839B2 (en) *	2002-08-21	2009-06-30	Industrial Research Limited	5h-pyrrolo[3,2-D] pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases
CA2497765A1 (en)	2002-09-27	2004-04-08	Sumitomo Pharmaceuticals Co., Ltd.	8-hydroxy substituted adenine compounds and uses thereof
EP1646614A4 (en)	2003-07-01	2008-09-10	Merck & Co Inc	OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA
WO2005020892A2 (en)	2003-08-08	2005-03-10	Mitochroma Research, Inc.	Pharmaceutical compositions and methods for metabolic modulation
EP1667694B1 (en)	2003-09-05	2010-04-28	Anadys Pharmaceuticals, Inc.	Tlr7 ligands for the treatment of hepatitis c
AR046172A1 (es) *	2003-10-03	2005-11-30	3M Innovative Properties Co	Pirazolopiridinas y sus analogos; composiciones farmaceuticas que los contienen y su uso en la inhibicion de la biosintesis de citocinas
BRPI0509258A8 (pt) *	2004-03-26	2019-01-22	Astrazeneca Ab	composto de 8-oxoadenina 9-substituída
WO2005092892A1 (ja)	2004-03-26	2005-10-06	Dainippon Sumitomo Pharma Co., Ltd.	８−オキソアデニン化合物
MXPA06011423A (es)	2004-04-02	2007-01-23	Osi Pharm Inc	Inhibidores de proteina cinasa heterobiciclica sustituida en el anillo 6,6-biciclico.
MXPA06013250A (es)	2004-05-14	2007-02-28	Abbott Lab	Inhibidores de quinasa como agentes terapeuticos.
JP2007530579A (ja) *	2004-06-10	2007-11-01	スリーエムイノベイティブプロパティズカンパニー	アミド置換イミダゾピリジン、イミダゾキノリン、およびイミダゾナフチリジン
US20060029642A1 (en)	2004-08-03	2006-02-09	Dusan Miljkovic	Methods and compositions for improved chromium complexes
GB0420719D0 (en)	2004-09-17	2004-10-20	Addex Pharmaceuticals Sa	Novel allosteric modulators
EA200702235A1 (ru)	2005-05-04	2008-04-28	Пфайзер Лимитед	Производные 2-амидо-6-амино-8-оксопурина в качестве модуляторов toll-подобных рецепторов для лечения рака и вирусных инфекций, таких как гепатит с
NZ540160A (en)	2005-05-20	2008-03-28	Einstein Coll Med	Inhibitors of nucleoside phosphorylases
JPWO2006126718A1 (ja) *	2005-05-27	2008-12-25	田辺三菱製薬株式会社	ピラゾロピリミジン誘導体
US7932257B2 (en) *	2005-07-22	2011-04-26	Sunesis Pharmaceuticals, Inc.	Substituted pyrazolo[4,3-d]pyrimidines as aurora kinase inhibitors
CA2620182A1 (en)	2005-08-22	2007-03-01	Dennis A. Carson	Tlr agonists
RU2008110908A (ru)	2005-08-25	2009-09-27	Шеринг Корпорейшн (US)	Производные имидазола в качестве функционально селективных агонистов альфа2с адренорецепторов
US8003624B2 (en)	2005-08-25	2011-08-23	Schering Corporation	Functionally selective ALPHA2C adrenoreceptor agonists
CN101253173A (zh)	2005-09-02	2008-08-27	辉瑞有限公司	羟基取代的1h-咪唑并吡啶和方法
TW200801003A (en)	2005-09-16	2008-01-01	Astrazeneca Ab	Novel compounds
WO2007034917A1 (ja)	2005-09-22	2007-03-29	Dainippon Sumitomo Pharma Co., Ltd.	新規なアデニン化合物
JPWO2007034881A1 (ja)	2005-09-22	2009-03-26	大日本住友製薬株式会社	新規アデニン化合物
EP1939202A4 (en)	2005-09-22	2010-06-16	Dainippon Sumitomo Pharma Co	NEW ADENINE CONNECTION
TW200745114A (en)	2005-09-22	2007-12-16	Astrazeneca Ab	Novel compounds
JPWO2007034882A1 (ja)	2005-09-22	2009-03-26	大日本住友製薬株式会社	新規アデニン化合物
EP1939200A4 (en)	2005-09-22	2010-06-16	Dainippon Sumitomo Pharma Co	NEW ADENINE CONNECTION
CN1947717B (zh)	2005-10-14	2012-09-26	卓敏	选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用
AU2007216247A1 (en)	2006-02-17	2007-08-23	Pfizer Limited	3 -deazapurine derivatives as TLR7 modulators
EP1999376A1 (de)	2006-03-24	2008-12-10	Siemens Aktiengesellschaft	Verfahren zum betrieb einer verdichtereinheit, verdichtereinheit
WO2007110868A2 (en)	2006-03-28	2007-10-04	Atir Holding S.A.	Heterocyclic compounds and uses thereof in the treatment of sexual disorders
GB0610666D0 (en)	2006-05-30	2006-07-05	Glaxo Group Ltd	Fluid dispenser
US8846697B2 (en)	2006-05-31	2014-09-30	The Regents Of The University Of California	Purine analogs
JP2009542645A (ja)	2006-07-05	2009-12-03	アストラゼネカ・アクチエボラーグ	Ｔｌｒ７のモジュレーターとして作用する８−オキソアデニン誘導体
US8338593B2 (en)	2006-07-07	2012-12-25	Gilead Sciences, Inc.	Modulators of toll-like receptor 7
TW200831105A (en)	2006-12-14	2008-08-01	Astrazeneca Ab	Novel compounds
JP2010519186A (ja)	2007-02-19	2010-06-03	スミスクラインビーチャムコーポレーション	免疫調節物質としてのプリン誘導体
EP2132209B8 (en)	2007-03-19	2014-04-16	AstraZeneca AB	9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7 ) modulators
JP5329444B2 (ja)	2007-03-19	2013-10-30	アストラゼネカ・アクチエボラーグ	Ｔｏｌｌ様受容体（ｔｌｒ７）モジュレーターとしての９−置換−８−オキソ−アデニン化合物
EP2138497A4 (en)	2007-03-20	2012-01-04	Dainippon Sumitomo Pharma Co	NEW ADENINE CONNECTION
TW200902018A (en)	2007-03-20	2009-01-16	Dainippon Sumitomo Pharma Co	Novel adenine compound
US7928111B2 (en)	2007-06-08	2011-04-19	Senomyx, Inc.	Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
EP2170888B1 (en)	2007-06-29	2015-04-22	Gilead Sciences, Inc.	Purine derivatives and their use as modulators of toll-like receptor 7
GB0715087D0 (en)	2007-08-03	2007-09-12	Summit Corp Plc	Drug combinations for the treatment of duchenne muscular dystrophy
CN101842098A (zh)	2007-08-10	2010-09-22	基因实验室技术有限公司	用于治疗病毒感染的含氮的二环化学实体
UY31531A1 (es)	2007-12-17	2009-08-03		Sales derivadas de 8-oxoadenina composiciones farmacéuticas que las contienen y su uso en terapia como moduladores de receptor tipo toll (tlr)
WO2009151910A2 (en)	2008-05-25	2009-12-17	Wyeth	Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
US8946239B2 (en)	2008-07-10	2015-02-03	Duquesne University Of The Holy Spirit	Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof
WO2010018132A1 (en)	2008-08-11	2010-02-18	Smithkline Beecham Corporation	Compounds
JP5519670B2 (ja)	2008-08-11	2014-06-11	グラクソスミスクラインエルエルシー	アレルギー性、炎症性及び感染性疾患治療用のプリン誘導体
CN102176911B (zh)	2008-08-11	2014-12-10	葛兰素史密丝克莱恩有限责任公司	新的腺嘌呤衍生物
UA103195C2 (uk) *	2008-08-11	2013-09-25	Глаксосмитклайн Ллк	Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
BRPI0917458A2 (pt)	2008-08-11	2015-12-01	Glaxosmithkline Llc	composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto
US8802684B2 (en)	2008-08-11	2014-08-12	Glaxosmithkline Llc	Adenine derivatives
CN102548999A (zh)	2009-01-20	2012-07-04	山东轩竹医药科技有限公司	含有取代的含氮稠杂环的头孢菌素衍生物
US9044481B2 (en)	2009-08-07	2015-06-02	Glaxosmithkline Biologicals S.A.	Lipidated oxoadenine derivatives
US8575340B2 (en)	2010-02-10	2013-11-05	Glaxosmithkline Llc	Purine derivatives and their pharmaceutical uses
RS53745B1 (sr)	2010-02-10	2015-06-30	Glaxosmithkline Llc	6-amino-2-{[(1s)-1-metilbutil]oksi}-9-[5-(1-piperidinil)pentil]-7,9-dihidro-8h-purin-8-on-maleat
WO2012009258A2 (en)	2010-07-13	2012-01-19	Edward Roberts	Peptidomimetic galanin receptor modulators
US20120171229A1 (en)	2010-12-30	2012-07-05	Selecta Biosciences, Inc.	Synthetic nanocarriers with reactive groups that release biologically active agents
USRE47009E1 (en)	2011-02-01	2018-08-28	The Children's Hospital Of Philadelphia	HDAC inhibitors and therapeutic methods using the same
JP5813785B2 (ja)	2011-02-04	2015-11-17	デュケインユニバーシティーオブザホリースピリット	抗チューブリン活性を有する二環式および三環式のピリミジンチロシンキナーゼ阻害剤ならびに患者の処置方法
WO2013014052A1 (en)	2011-07-22	2013-01-31	Glaxosmithkline Llc	Composition
US9173872B2 (en)	2012-08-24	2015-11-03	Glaxosmithkline Llc	Pyrazolopyrimidine compounds
SMT201700378T1 (it)	2012-11-20	2017-09-07	Glaxosmithkline Llc	Nuovi composti
KR20150085081A (ko)	2012-11-20	2015-07-22	글락소스미스클라인 엘엘씨	신규 화합물
JP6216387B2 (ja)	2012-11-20	2017-10-18	グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅＬＬＣ	新規化合物
KR20160124157A (ko)	2014-02-20	2016-10-26	글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드	인간 인터페론의 유도인자로서의 피롤로[3,2]피리미딘 유도체

2013
- 2013-08-22 US US13/973,466 patent/US9173872B2/en active Active
- 2013-08-22 TW TW102130088A patent/TWI625331B/zh not_active IP Right Cessation
- 2013-08-22 US US14/423,400 patent/US9555036B2/en active Active
- 2013-08-22 JP JP2015528644A patent/JP6196674B2/ja not_active Expired - Fee Related
- 2013-08-22 AR ARP130102974 patent/AR092198A1/es unknown
- 2013-08-22 CN CN201380055759.3A patent/CN104755480B/zh not_active Expired - Fee Related
- 2013-08-22 NZ NZ704224A patent/NZ704224A/en not_active IP Right Cessation
- 2013-08-22 MX MX2015002433A patent/MX359671B/es active IP Right Grant
- 2013-08-22 CA CA2880576A patent/CA2880576A1/en not_active Abandoned
- 2013-08-22 UA UAA201501077A patent/UA114109C2/uk unknown
- 2013-08-22 BR BR112015003259A patent/BR112015003259A2/pt not_active Application Discontinuation
- 2013-08-22 MY MYPI2015700519A patent/MY175676A/en unknown
- 2013-08-22 SG SG11201500787YA patent/SG11201500787YA/en unknown
- 2013-08-22 KR KR1020157007428A patent/KR20150046267A/ko not_active Withdrawn
- 2013-08-22 UY UY0001034987A patent/UY34987A/es not_active Application Discontinuation
- 2013-08-22 PE PE2015000238A patent/PE20150730A1/es active IP Right Grant
- 2013-08-22 EP EP13756249.2A patent/EP2888264B1/en active Active
- 2013-08-22 WO PCT/US2013/056107 patent/WO2014031815A1/en not_active Ceased
- 2013-08-22 ES ES13756249.2T patent/ES2653254T3/es active Active
- 2013-08-22 EA EA201590189A patent/EA026354B1/ru not_active IP Right Cessation
- 2013-08-22 AU AU2013305790A patent/AU2013305790B2/en not_active Ceased
- 2013-08-22 HK HK15111867.0A patent/HK1211029A1/xx unknown
2015
- 2015-01-29 IL IL236983A patent/IL236983B/en active IP Right Grant
- 2015-02-09 CR CR20150061A patent/CR20150061A/es unknown
- 2015-02-12 DO DO2015000027A patent/DOP2015000027A/es unknown
- 2015-02-20 CL CL2015000408A patent/CL2015000408A1/es unknown
- 2015-02-24 PH PH12015500401A patent/PH12015500401A1/en unknown
- 2015-10-01 US US14/872,620 patent/US9662336B2/en not_active Expired - Fee Related
2017
- 2017-04-26 US US15/497,852 patent/US10022442B2/en active Active
2018
- 2018-06-14 US US16/008,421 patent/US20180289800A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20180289800A1 (en)	2018-10-11
PE20150730A1 (es)	2015-06-02
EP2888264A1 (en)	2015-07-01
US20140056928A1 (en)	2014-02-27
SG11201500787YA (en)	2015-03-30
NZ704224A (en)	2018-04-27
ES2653254T3 (es)	2018-02-06
DOP2015000027A (es)	2015-04-15
CR20150061A (es)	2015-04-14
CA2880576A1 (en)	2014-02-27
EA026354B1 (ru)	2017-03-31
PH12015500401B1 (en)	2015-04-27
MX359671B (es)	2018-10-05
MX2015002433A (es)	2015-06-22
US20160022686A1 (en)	2016-01-28
AR092198A1 (es)	2015-04-08
CN104755480A (zh)	2015-07-01
EA201590189A1 (ru)	2015-08-31
TWI625331B (zh)	2018-06-01
BR112015003259A2 (pt)	2017-08-08
JP2015530377A (ja)	2015-10-15
AU2013305790A1 (en)	2015-02-26
US20170290910A1 (en)	2017-10-12
UA114109C2 (xx)	2017-04-25
EP2888264B1 (en)	2017-09-27
US9555036B2 (en)	2017-01-31
US9173872B2 (en)	2015-11-03
CN104755480B (zh)	2017-04-12
PH12015500401A1 (en)	2015-04-27
WO2014031815A1 (en)	2014-02-27
US9662336B2 (en)	2017-05-30
US20150225403A1 (en)	2015-08-13
MY175676A (en)	2020-07-06
TW201420588A (zh)	2014-06-01
US10022442B2 (en)	2018-07-17
UY34987A (es)	2014-03-31
IL236983B (en)	2018-02-28
AU2013305790B2 (en)	2016-09-08
HK1211029A1 (en)	2016-05-13
JP6196674B2 (ja)	2017-09-13
KR20150046267A (ko)	2015-04-29

Publication	Publication Date	Title
CL2015000295A1 (es)	2015-04-24	Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
CL2014002412A1 (es)	2015-03-06	Compuestos derivados de pirido[4,3-d]pirimidina, como inhibidores de mek; composicion farmaceutica que los comprende; y su uso para el tratamiento de enfermedades inflamatorias, infecciones, trastornos autoinmunes, enfermedades metabolicas y enfermedades malignas, entre otras.
CL2014001793A1 (es)	2014-11-07	Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
CL2014002093A1 (es)	2014-11-21	Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas.
CL2015003686A1 (es)	2016-08-19	Derivados de pirrolo[3,2-d]pirimidina para el tratamiento de infecciones víricas y otras enfermedades
CL2014002880A1 (es)	2015-02-06	Compuestos derivados de heterociclos nitrogenados o sus sales, inhibidores selectivos de la pde2a; medicamento que los comprende; y su uso para la profilaxis y tratamiento de la esquizofrenia.
CL2016001895A1 (es)	2016-12-09	Compuestos
CL2013003051A1 (es)	2014-07-11	Compuestos derivados de pirazolo (4.3-d) pirimidinas, inhibidores de quinasa; composicion farmaceutica; y uso para el tratamiento de enfermedades y trastornos del aparato respiratorio
DOP2015000274A (es)	2015-12-31	Compuestos químicos
CL2014000746A1 (es)	2014-10-03	Compuestos derivados de 3-pirimidin-4-il-oxazolidin-2-ona y sus sales, como inhibidores de las proteinas idh mutantes; composicion farmaceutica que los comprende, utiles para el tratamiento de trastornos de la proliferacion celular tal como el cancer.
DOP2016000271A (es)	2017-04-16	Compuestos de heteroarilo o arilo bicíclicos fusionados
DK3418281T3 (da)	2020-12-07	Pyrazolo[1,5-a]pyrimidiner, der er anvendelige som inhibitorer af atr-kinase til behandling af cancersygdomme
CL2015000706A1 (es)	2015-08-07	Compuestos derivados biciclicos conteniendo nitrogeno y sus sales; su proceso de obtencion; composicion farmaceutica que los comprende; y su uso para el tratamiento o profilaxis de estados patologicos renales, hepaticos, inflamatorios, del sistema nervioso, enfermedades fibroticas y rechazo agudo y cronico del trasplante de organos.
NI201800042A (es)	2018-06-21	Nuevos derivados de pirrolo[2,3-d]pirimidina como inhibidores duales de dyrk1/clk1
MX2015003140A (es)	2015-12-16	Formulaciones de enzalutamida.
CL2014002301A1 (es)	2015-05-08	Compuestos derivados de pirimidin piridinas sustituidas, inhibidores de serina/treonina cinasas; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; combinacion farmaceutica; uso para el tratamiento de una enfermedad hiperproliferativa tal como melanoma, cancer, leucemias y una enfermedad inflamatoria como artritis y reumatismo entre otras.
MX386935B (es)	2025-03-04	Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
CL2014003566A1 (es)	2015-04-10	Compuestos derivados de 7h-pirrolo[2,3-d]pirimidinas 4-(amimo-sustituidas), inhibidores de lrrk2; composicion farmaceutica que los comprende; y metodo para tratar la enfermedad de parkinson.
BR112016000489A2 (pt)	2017-07-25	composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos
BR112014028395A2 (pt)	2017-06-27	derivados 3,4-di-hidro-2h-pirido[1,2-a] pirazina-1,6-diona substituídos úteis para o tratamento de (inter alia) doença de alzheimer
CL2015002635A1 (es)	2016-02-19	Compuestos y composiciones para el tratamiento de enfermedades parasitarias
MX386584B (es)	2025-03-04	Composiciones de liberación retardada de linaclotida.
PT2872497T (pt)	2017-04-24	Derivados de cromanilo para o tratamento de doenças mitocondriais
CL2014001047A1 (es)	2014-11-07	Compuestos heterociclicos derivados de pirazina; composicion y combinacion farmaceutica que los contienen y el uso en enfermedades respiratorias y alergicas.
CL2015000717A1 (es)	2015-06-19	Compuestos derivados de piridinonas biciclicas y sus sales; composicion farmaceutica que los comprende; y su uso para el tratamiento de la neurodegeneracion y trastornos psiquiatricos, que incluyen enfermedad de alzheimer o enfermedad de niemann-pick tipo c.